FHD-909

FHD-909 (LY4050784) (10 days) potently and selectively inhibits proliferation of SMARCA4-mutant non-small cell lung cancer cell lines in vitro, with the median IC₅₀ for SMARCA4-mutant lines being 33-fold lower than that for SMARCA4-wildtype lines^[1].
FHD-909 (0.1-100 nM) exhibits additive and synergistic anti-proliferative activity when combined with Cisplatin (HY-17394), Paclitaxel (HY-B0015) or Pemetrexed (HY-10820) in A549 SMARCA4-mutant non-small cell lung cancer cell lines in vitro^[1].
FHD-909 (0.1-100 nM with olomorasib; 0.1-100 nM with LY4066434) exhibits synergistic anti-proliferative activity when combined with Olomorasib (HY-132980) or LY4066434 in NCI-H2030 SMARCA4-mutant, KRAS^G12C non-small cell lung cancer cell lines in vitro^[1].
FHD-909 (0.1-1000 nM in PATU-8988T cells; 0.1-1000 nM in SNU-407 cells) exhibits synergistic anti-proliferative activity when combined with LY3962673 in PATU-8988T pancreatic ductal adenocarcinoma cell lines and SNU-407 colorectal cancer cell lines in vitro^[1].
FHD-909 (1-10000 nM in A549 cells; 1-10000 nM in PATU-8988T cells) exhibits synergistic anti-proliferative activity when combined with LY4066434 in A549 non-small cell lung cancer cell lines and PATU-8988T pancreatic ductal adenocarcinoma cell lines in vitro^[1].
FHD-909 potently inhibits purified BRM ATPase with an IC₅₀ of 0.0025 μM and is 35.69-fold selective for BRM over purified BRG1 ATPase^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.